Sara Redaelli

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Rocco Piazza, Simona Valletta, Nils Winkelmann et al. · Nature Genetics · 2012 · 425 citations · Full text

Medicine, Genetics, Oncology +11

<i>In vitro</i> and <i>In vivo</i> Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells

Miriam Puttini, Addolorata Maria Luce Coluccia, Frank Boschelli et al. · Cancer Research · 2006 · 371 citations

Medicine, Oncology, Pharmacology +11

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

Carlo Gambacorti‐Passerini, Francesca Farina, Alessandra Stasia et al. · JNCI Journal of the National Cancer Institute · 2014 · 279 citations

Medicine, Oncology, Pharmacology +16

Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation

Addolorata Maria Luce Coluccia, Angelo Vacca, Mireia Duñach et al. · The EMBO Journal · 2007 · 215 citations · Full text

Medicine, Cancer Biology, Oncology +9

Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study

Silvia Mori, Elisabetta Vagge, Philipp le Coutre et al. · American Journal of Hematology · 2015 · 209 citations · Full text

Medicine, Hematology, Pharmacotherapy +11